Tris Pharma, Inc. Expands Ibuprofen Recall

News
Article

The company is recalling three additional lots of Ibuprofen Oral Suspension Drops, USP, 50 mg per 1.25 mL because of a higher concentration of ibuprofen.

Tris Pharma, Inc. announced on January 29, 2019 that it was recalling three additional lots of Ibuprofen Oral Suspension Drops, USP, 50 mg per 1.25 mL because some batches had higher levels of ibuprofen concentration up to 10% above the specified limit. This recall expands on a similar recall in December 2018.

While no adverse events associated with the recall have been reported as of January 29, infants that are already susceptible to the effects of ibuprofen may be more susceptible to the higher potency level of the recalled lots and could potentially be more vulnerable to permanent NSAID-associated renal injury, according to the company.

The recalled lots were manufactured as CVS Health: Infants’ Ibuprofen Concentrated Oral Suspension, USP, 50 mg per 1.25 mL, in 0.5 oz. bottle for CVS Pharmacy and Equate: Infants’ Ibuprofen Concentrated Oral Suspension, USP, 50 mg per 1.25 mL, in 1.0 oz. bottle for Wal-Mart Stores. The company has advised retailers to stop distributing the affected lots.

Source: FDA

 

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes